President Trump's bout of COVID-19 launched countless headlines regarding the some of the leading experimental treatments he'd be receiving - therapeutics…
McAlinden Research PartnersOctober 13, 2020
New developments in advanced methods of CRISPR, particularly in base and prime editing, continue to propel the popularity of the…
McAlinden Research PartnersSeptember 1, 2020
Treatments utilizing Clustered Regularly Interspace Short Palindromic Repeats (CRISPR), continue to rack up clinical success. The latest research on blood…
McAlinden Research PartnersJune 16, 2020
Though many sectors have been whacked by the Coronavirus-related hurdles in 2020, research and development of the gene editing technology…
McAlinden Research PartnersMay 13, 2020
All sizes of pharmaceutical firms from giants like Johnson & Johnson to young guns like Moderna, yet to bring their…
McAlinden Research PartnersApril 1, 2020
The FDA and a number of major pharmaceutical firms have warned of drug shortages resulting from chemical plant shut downs…
McAlinden Research PartnersMarch 3, 2020
A virus called 2019-nCoV that emerged last month in Central China is spreading so fast that it risks becoming a…
McAlinden Research PartnersJanuary 23, 2020
New research on CRISPR techniques that could provide treatments and improved diagnostics for several major viruses and other medical conditions…
McAlinden Research PartnersNovember 13, 2019
